Disease Spotlight: NMOSD
The NeurologyLive® NMOSD Disease Spotlight page provides specific and in-depth updates, as well as multiple expert conversations, data readouts, and clinical coverage related to the management of patients with the demyelinating disorder.
FDA Approves Alexion's Ravulizumab-cwvz for Neuromyelitis Optica Spectrum Disorder
March 25th 2024Article
The approval is supported by phase 3 data which showed ravulizumab-cwvz met its primary end point of time to first on-trial relapse, with no relapses observed in 58 patients with NMOSD over a median treatment duration of 73 weeks.
